1. Introduction {#sec1}
===============

Malarial infection is an important tropical mosquito-borne infectious disease that kills approximately three million per year. Statistics show that close to five billion episodes of clinical illness possibly meriting antimalarial therapy occur throughout the world, with Africa having more than 90% of this burden \[[@B24], [@B25]\]. Over the years, different categories of plasmodia specie (*Plasmodium falciparum, ovale, vivax, and malaria*) evolved with several newly observed mechanisms of resistance. The emergence and spread across sub-Saharan Africa of *Plasmodium falciparum* resistance among others to the inexpensive antimalarials chloroquine and sulfadoxine-pyrimethamine have worsened the pandemic and hampered the socioeconomic development of affected countries \[[@B17]\]. Following increased resistance of malaria parasites to conventional drugs in the malarial regions of the world, the WHO has been promoting artemisinin-based combination therapy (ACT) for treating uncomplicated malaria \[[@B24], [@B16]\]. Artemisinin and its related compounds enhance efficacy of ACT and have the potential of lowering the rate at which resistance emerges and spreads. The ACTs are particularly known to be most effective because of their high killing rates, and they have become the mainstay chemotherapeutic agents for malaria \[[@B14]\]. Under low transmission intensity,ACTshave an additional public health benefit of reducing the overallmalariatransmission and studies have recently demonstrated this synergistic benefit under high transmission \[[@B3]\]. ACTs offer the advantages of countering the increasing challenge of antimalarial drug resistance as well as an improved and highly effective treatment \[[@B4], [@B6]\]. In fact, several countries in Africa have adopted the use of ACT combination methods as far back as 2000, and it has provided an effective management central to the reduction of malaria mortality and morbidity worldwide. However, unfortunately, only a minority of those affected by malaria have access to prompt effective treatment in most parts of Africa \[[@B7], [@B19]\].

There has been increasing and expanding knowledge of safety profiles of ACT with focus on animals as well as human data including pharmacovigilance activities in the implementation process of therapy changes in order to evaluate fully its effect on the populace \[[@B8]\].

In areas where malaria is endemic, patients often prefer one ACT to another. Up to now, evidence abounds that despite the limited malaria parasite resistance to ACT therapy, their in vivo as well as in vitro assessment remains an ongoing process. Whether as a single monotherapy or in combination, the fate of ACTs in populations required a continuous evaluation and several authors have documented the reports of their studies \[[@B22]--[@B23]\]. Interestingly, of these studies, renal antioxidants activities of ACTs as well as lipid peroxidation however are rarely discussed. Therefore, in order to aid diagnosis and enhance therapeutic options, in this present study, we evaluated a subacute therapeutic administration of artemether-lumefantrine and artesunate-amodiaquine combination on plasma total cholesterol, renal antioxidants, and organ weights in an experimental rat model.

2. Materials and Methods {#sec2}
========================

2.1. Drug and Chemicals {#sec2.1}
-----------------------

Artemether + lumefantrine (lonart) and Artesunate + amodiaquine (camosunate) Bliss Gvs Pharma Ltd., India, and Adams Pharmaceutical Co. Ltd. (China). Thiobarbituric acid (TBA) and 5′,5′-dithiobis-2-nitrobenzoate (Ellman\'s reagent) were purchased from Sigma Chemical Company (USA). Reduced glutathione (GSH), metaphosphoric acid, and trichloroacetic acid (TCA) were purchased from J. I. Baker (USA). Total cholesterol (TC) and lactate dehydrogenase assay kits was obtained from Randox Laboratory (Crumlin, UK). All other chemicals and reagents used were of analytical grade.

2.2. Animals {#sec2.2}
------------

Sixteen (16) white albino rats weighing between 120 and 180 g of both sexes were obtained from Covenant Farm Academy, Iwo Road, Ibadan, Oyo-State, Nigeria, and were housed within the experimental animal handling facility of the College of Natural Sciences, Redeemers University, Nigeria, at ambient temperature and humidity with a 12 h light/12 h dark schedule. They were placed on rat pellets diet and water *ad libitum* during the period of acclimatization and throughout the period of the experiment. Study was in accordance with established guidelines for care and use of the laboratory animals in biomedical research. The experiment was approved by the Animal Ethics Committee of Redeemer\'s University.

3. Experimental Design {#sec3}
======================

Sixteen (16) white albino rats were divided into three groups. Treatment was provided in all groups two times daily at therapeutic doses calculated based on the assumed average weight of 70 kg for a physiological man. Group A (*n* = 5) was given no treatment and served as negative control in this study. Group B (*n* = 6) was administered therapeutic dose of artemeter-lumefantrine (lonart), 1.14/6.86 mg/kg/d). Group C (*n* = 5) was administered therapeutic dose of artesunate-amodiaquine (camosunate), 2.86/8.58 mg/kg/d). The treatments (using intragastric feeding needle) were continued for seven days.

3.1. Necropsy {#sec3.1}
-------------

All animals were sacrificed by cervical dislocation, absence of general anesthesia, 24 hours following the last treatment and blood collected by cardiac puncture into lithium heparin bottles. Plasma was separated after centrifugation at 4,500 g at room temperature for 25 minutes. The kidney was carefully excised, cleared of adhering tissues, and weighed. The weight was recorded in grams and expressed as g/kg body weight. The excised kidney was weighed and homogenized in four volumes of 100 mM phosphate buffer (pH 7.4). All the proceedings were carried out at a temperature not exceeding 4°C. The plasma and kidney homogenate obtained from each animal were then analyzed to assess kidney antioxidants levels and other biochemical parameters.

3.2. Biochemical Analysis {#sec3.2}
-------------------------

GSH level was estimated at 412 nm following the method of Beutler et al. \[[@B5a], [@B5b]\]. Lipid peroxidation was estimated spectrophotometrically by the thiobarbituric acid reactive substance (TBARS) method as described by Varshney and Kale \[[@B30]\] and expressed in terms of malondialdehyde (MDA) formed per mg protein. GST activity determined according to Habig et al. \[[@B12]\]. Plasma total cholesterol (TC) concentration was estimated following the principle described by Trinder \[[@B29]\]. Lactate dehydrogenase activity was estimated in plasma according to the procedures using Randox commercial kit. Catalase activity was determined according to the methods of Sinha \[[@B26]\]. Superoxide dismutase (SOD) activity was determined by the method of Misra and Fridovich \[[@B18]\]. Myeloperoxidase (MPO) activity, an indicator of polymorphonuclear leukocyte accumulation, was determined according to the method of Eiserich et al. \[[@B9]\].

4. Statistics {#sec4}
=============

Differences between groups were determined by one-way analysis of variance (ANOVA), and post hoc testing was performed for intergroup comparisons using the least significant difference (LSD) \[[@B15]\]. Data presented are mean ± standard error of mean (SEM) and were analyzed using Statistical Package for Social Sciences (SPSS) software for windows. *P* \< 0.05 was considered significant.

5. Results {#sec5}
==========

5.1. Effect of A + L and A + A on Plasma Biomarkers {#sec5.1}
---------------------------------------------------

[Figure 1](#fig1){ref-type="fig"} summarizes the effects of artemether-lumefantrine and artesunate-amodiaquine combination on plasma total cholesterol and lactate dehydrogenase levels in rats. From the results, total cholesterol levels decreased in plasma of all animals given therapeutic doses of artemether-lumefantrine (1.14/6.86 mg/kg/d) and artesunate-amodiaquine (2.86/8.58 mg/kg/d), although statistics showed this not to be statistically significant (*P* \> 0.05) when compared with control. Furthermore, we assessed lactate dehydrogenase (LDH) as a biomarker of renal function. Results show that artemether-lumefantrine (1.14/6.86 mg/kg/d) administered at a therapeutic dose increased LDH insignificantly (*P* \> 0.05) while equal molar of artesunate-amodiaquine (2.86/8.58 mg/kg/d) therapeutically increased LDH level significantly (*P* \< 0.05) in this study ([Figure 1](#fig1){ref-type="fig"}).

5.2. Effect of A + L and A + A on Renal Antioxidant Status {#sec5.2}
----------------------------------------------------------

From the result obtained, catalase slightly increased insignificantly (*P* \> 0.05) in both artemeter-lumefantrine (1.14/6.86 mg/kg/d) and artesunate-amodiaquine (2.86/8.58 mg/kg/d) when compared with the control group that was given no treatment. Also, superoxide dismutase increased insignificantly as well, although this was more pronounced in artesunate-amodiaquine than artemeter-lumefantrine when compared with control. Glutathione S-transferase level increased insignificantly (*P* \> 0.05) in artesunate-amodiaquine-(2.86/8.58 mg/kg/d) treated rats when compared with control. However, the effect of artemether-lumefantrine (1.14/6.86 mg/kg/d) on the GST activity was similar to those of control animals. The level of total glutathione was not to any extent altered in animals treated with therapeutic dose of artemether-lumefantrine (1.14/6.86 mg/kg/d) when compared with control whereas artesunate-amodiaquine (2.86/8.58 mg/kg/d) increased GSH four times the control group, although this was not statistically significant ([Table 1](#tab1){ref-type="table"}).

5.3. Effect of A + L and A + A on Lipid Peroxidation and Myeloperoxidase Levels {#sec5.3}
-------------------------------------------------------------------------------

Lipid peroxidation was measured as malondialdehyde in this study. Artemether-lumefantrine (1.14/6.86 mg/kg/d) and artesunate-amodiaquine (2.86/8.58 mg/kg/d) both at therapeutic doses significantly increased (*P* \< 0.05) MDA level by 76.5% and 82.4% when compared with control ([Table 1](#tab1){ref-type="table"}).

Myeloperoxidase activity was also evaluated in rat kidney following artemether-lumefantrine (1.14/6.86 mg/kg/d) and artesunate-amodiaquine (2.86/8.58 mg/kg/d) administration but was not significantly increased (*P* \> 0.05) when compared with that of control animals ([Figure 1](#fig1){ref-type="fig"}).

5.4. Effect of A + L and A + A on Rat Organ Weights {#sec5.4}
---------------------------------------------------

Artemether-lumefantrine (1.14/6.86 mg/kg/d) and artesunate-amodiaquine (2.86/8.58 mg/kg/d) given at therapeutic doses did not alter kidney, liver, and brain weights, respectively, in these animals when compared with control. However, artemether-lumefantrine (1.14/6.86 mg/kg/d) but not artesunate-amodiaquine (2.86/8.58 mg/kg/d) increased lung weight insignificantly when compared with control. Also, artesunate-amodiaquine (2.86/8.58 mg/kg/d) significantly decreased (*P* \< 0.05) heart weight by 27.2% whereas artemether-lumefantrine (1.14/6.86 mg/kg/d) did not alter the weight of the heart when compared with the control in this experiment ([Table 2](#tab2){ref-type="table"}).

6. Discussion {#sec6}
=============

Because of the high resistance and toxicity profiles of the older antimalarial agents, virtually all malaria-endemic countries have almost switched antimalarial drug policy to artemisinin combination therapies (ACTs). The change of first-line treatment of uncomplicated malaria to artemisinin combination therapy (ACT) is widespread in Africa \[[@B8]\], and there is need for continuous monitoring to keep track of any negative effects on various organs and biochemical parameters. In our present study, we evaluated a subacute therapeutic administration of two different ACTs, artemether-lumefantrine and artesunate-amodiaquine combination on total cholesterol, renal antioxidants, and organ weights in an experimental rat model. Artesunate-amodiaquine combination alone showed a higher but insignificant free scavenging activities in superoxide dismutase (*P* = 0.07), catalase (*P* \> 0.05), and total glutathione (*P* \> 0.05) levels when compared with the artemether-lumefantrine-treated group. Similarly, plasma total cholesterol remained unaltered insignificantly (*P* \> 0.05) in these animals when compared with control group. Our study supports the earlier suggestion of Obianime and Aprioku \[[@B23]\] on the anticholesteremic action of ACTs.

MDA is a good indication of the degree of lipid peroxidation and tissue damage. The MDA levels in treated rat significantly increased when compared with the control group. There was a significant increase (*P* \< 0.05) in malondialdehyde levels in both artemether-lumefantrine-(1.14/6.86 mg/kg/d) and artesunate-amodiaquine-(2.86/8.58 mg/kg/d) treated rats when compared with that of control rats. This agrees with another study that reported an increase in testis malondialdehyde levels in rats administered 10 mg/60 mg/kg b.w of artemether-lumefantrine for 3 days, indicating a clear manifestation of excessive formation of free radicals and activation of lipid peroxidation systems \[[@B27]\]. In addition, artesunate-amodiaquine but not artemeter-lumefantrine increased significantly (*P* \< 0.05) lactate dehydrogenase level when compared with control. While we observed for the first time that artesunate-amodiaquine may play a role in lactate metabolism, some earlier studies have as well demonstrated cardiac modulatory properties of artesunate, and atroquinine-like compounds \[[@B28], [@B2], [@B1]\]. Nosten and White \[[@B21]\] had also reported that artemisinin and its derivatives on their own may have relatively low toxicological effects with the suggestion that any toxicity observed in artemisinin combination treatments may be due to the partner agent(s). However, further studies may be required to unfold the mechanisms by which ACT modulates lactate metabolism as well as the cardiac functions. As seen in our study, the effectiveness of artesunate-amodiaquine combination or other ACTs therapy is not without side effects. This has in part been attributed to the transient drug-induced fever of artesunate and its transient first-degree heart block reported as a rare event \[[@B31]\]. It is therefore necessary that studies involving ACTs be given an urgent attention and caution be exercised in patients with history of cardiac disorders. Analysis of organ weight in toxicology studies is an important endpoint for identification of potentially harmful effects of chemicals. In this study, kidney, liver, lung, and brain weights in relation to body weight were not significantly (*P* \> 0.05) altered except for artesunate-amodiaquine which decreased heart weight by 27.2% when compared with control. This correlates with a recent study which reported that dihydroartemisinin-piperaquine, artesunate-amodiaquine, artesunate-sulphadoxine/pyrimethamine, artemether plus lumefantrine, and artesunate mefloquine combinations elicited no significant treatment-related histopathological changes in the liver and kidney in experimental mice \[[@B10]\]. Based on these observations, the authors concluded that the ACTs as administered presently for the treatment of malaria are relatively safe. In conclusion, antimalarial activities of artesunate-amodiaquine and artemether-lumefantrine may preserve renal antioxidants as well as organ system effects in addition to their lowering of total cholesterol levels, though not statistically significant as observed in our experiment. However, as observed in this study, caution must be taken when administering doses above the therapeutic indications or chronic administration as these may predispose to oxidative damage and/or precipitate cardiac toxicity.

![Effect of artemether-lumefantrine and artesunate-amodiaquine combinations on total cholesterol, lactate dehydrogenase, and myeloperoxidase in rats. Results are expressed as mean ± SEM. \**P* \< 0.05 when compared with control. A + L: artemether + lumefantrine; A + A: artesunate + amodiaquine.](MRT2012-257986.001){#fig1}

###### 

Effects of artemether-lumefantrine and artesunate-amodiaquine combination on renal antioxidants and lipid peroxidation levels in rats.

  Treatments            CAT^a^         SOD^b^        GST^c^        GSH^c^          MDA^d^
  --------------------- -------------- ------------- ------------- --------------- -----------------
  Control               0.153 ± 0.01   0.24 ± 0.06   0.64 ± 0.03   0.022 ± 0.001   0.017 ± 0.002
  A + L                 0.160 ± 0.01   0.50 ± 0.21   0.63 ± 0.03   0.021 ± 0.001   0.030 ± 0.002\*
  (1.14/6.86 mg/kg/d)   (−4.6)^a^      (−108.3)^a^   (1.6)^a^      (4.5)^a^        (−76.5)^a^
  A + A                 0.170 ± 0.02   0.95 ± 0.04   0.49 ± 0.07   0.091 ± 0.065   0.031 ± 0.006\*
  (2.86/8.58 mg/kg/d)   (−11.1)^a^     (−295.8)^a^   (23.4)^a^     (−313.6)^a^     (−82.4)^a^

Results expressed as mean ±SEM. Values in parenthesis represent % change; (−): increase; (+): decrease, (a) % change relative to control group. \**P* \< 0.05 when compared with control. ^a^Expressed as units in *μ*mol/mL/mg protein; ^b^activity expressed as units/mg protein; ^c^activity expressed as nmoles/mg protein; ^d^concentration expressed as nmoles/mg protein; A + L: artemether + lumefantrine; A + A: artesunate + amodiaquine; CAT: catalase, SOD: superoxide dismutase, GST: glutathione s-transferase; GSH: total glutathione, MDA: malondialdehyde.

###### 

Effects of artemether-lumefantrine and artesunate-amodiaquine combination on organ systems relative to their body weights in rats.

  Treaments             LW^a^          KDW^a^        LGW^a^        HTW^a^          BRW^a^
  --------------------- -------------- ------------- ------------- --------------- -------------
  Control               26.94 ± 2.78   6.10 ± 0.64   7.99 ± 1.61   3.89 ± 0.45     3.45 ± 0.51
  A + L                 25.41 ± 1.75   5.36 ± 0.29   9.39 ± 1.95   3.53 ± 0.52     4.47 ± 0.09
  (1.14/6.86 mg/kg/d)   (6.68)^a^      (12.1)^a^     (−17.5)^a^    (9.3)^a^        (−26.2)^a^
  A + A                 24.30 ± 0.66   4.70 ± 0.64   7.02 ± 1.06   2.83 ± 0.15\*   5.64 ± 0.56
  (2.86/8.58 mg/kg/d)   (9.8)^a^       (23.0)^a^     (12.1)^a^     (27.2)^a^       (−63.5)^a^

Results expressed as mean ±SEM. Values in parenthesis represent % change; (−): increase; (+): decrease, (a) % change relative to control group. \**P* \< 0.05 when compared with control. ^a^Expressed units as g/kg body weight. A + L: artemether + lumefantrine; A + A: artesunate + amodiaquine; LW: liver weight; KDW: kidney weight; LGW: lung weight; HTW: heart weight; BRW; brain weight.
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